Pharmacoeconomics of PCSK9 inhibitors in 103 hypercholesterolemic patients referred for diagnosis and treatment to a cholesterol treatment center

Systematic review of published Phase 3 data on anti-PCSK9 monoclonal antibodies in patients with hypercholesterolaemia

(2016) Ioanna Gouni-Berthold et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Lifetime Perspectives on Primary Prevention of Atherosclerotic Cardiovascular Disease

(2016) Maarten J. G. Leening et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance

(2016) Steven E. Nissen et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dl despite maximal tolerated cholesterol lowering therapy

(2016) Charles J. Glueck et al.   Lipids in Health and Disease

Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia

(2015) Eliano Pio Navarese et al.   ANNALS OF INTERNAL MEDICINE

Productivity loss and indirect costs associated with cardiovascular events and related clinical procedures

(2015) Xue Song et al.   BMC HEALTH SERVICES RESEARCH

Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials

(2015) Xin-Lin Zhang et al.   BMC Medicine

The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis

(2015) Michael J. Lipinski et al.   EUROPEAN HEART JOURNAL

Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

(2015) Erik S. Stroes et al.   EUROPEAN HEART JOURNAL

New Therapies in the Treatment of High Cholesterol

(2015) William H. Shrank et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Reducing LDL with PCSK9 Inhibitors — The Clinical Benefit of Lipid Drugs

(2015) Brendan M. Everett et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

(2015) Jennifer G. Robinson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

(2015) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

PCSK9 Inhibitors: A Technology Worth Paying For?

(2015) William S. Weintraub et al.   PHARMACOECONOMICS

Lipid-Lowering Drug Therapy for CVD Prevention: Looking into the Future

(2015) Evan A. Stein et al.   Current Cardiology Reports

Prevalence of Cholesterol Treatment Eligibility and Medication Use Among Adults — United States, 2005–2012

(2015) Carla Mercado et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Should health insurers target prevention of cardiovascular disease?: a cost-effectiveness analysis of an individualised programme in Germany based on routine data

(2014) Majed Aljutaili et al.   BMC HEALTH SERVICES RESEARCH

Cascade screening based on genetic testing is cost-effective: Evidence for the implementation of models of care for familial hypercholesterolemia

(2014) Zanfina Ademi et al.   Journal of Clinical Lipidology

Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold

(2014) Peter J. Neumann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Further Insight Into the Cardiovascular Risk Calculator

(2014) Nancy R. Cook et al.   JAMA Internal Medicine

Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study

(2013) A. McConnachie et al.   EUROPEAN HEART JOURNAL

Differences in cholesterol management among states in relation to health insurance and race/ethnicity across the United States

(2013) Stanley H. Hsia et al.   Journal of Clinical Lipidology

Non–High-Density Lipoprotein Cholesterol, Guideline Targets, and Population Percentiles for Secondary Prevention in 1.3 Million Adults

(2013) Mohamed B. Elshazly et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Promoting Health and Wellness in the Workplace: A Unique Opportunity to Establish Primary and Extended Secondary Cardiovascular Risk Reduction Programs

(2013) Ross Arena et al.   MAYO CLINIC PROCEEDINGS

Budget impact of rosuvastatin initiation in high-risk hyperlipidemic patients from a US managed care perspective

(2013) C. Montouchet et al.   JOURNAL OF MEDICAL ECONOMICS

Lost productivity due to premature mortality in developed and emerging countries: an application to smoking cessation

(2012) Joseph Menzin et al.   BMC Medical Research Methodology

Prevalence of lipid abnormalities in the United States: The National Health and Nutrition Examination Survey 2003–2006

(2012) Peter P. Tóth et al.   Journal of Clinical Lipidology

Effect of Long-Term Exposure to Lower Low-Density Lipoprotein Cholesterol Beginning Early in Life on the Risk of Coronary Heart Disease

(2012) Brian A. Ference et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia

(2012) Eli M. Roth et al.   NEW ENGLAND JOURNAL OF MEDICINE

Value of Primordial and Primary Prevention for Cardiovascular Disease

(2011) William S. Weintraub et al.   CIRCULATION

Forecasting the Future of Cardiovascular Disease in the United States

(2011) Paul A. Heidenreich et al.   CIRCULATION

Vitamin D deficiency, myositis–myalgia, and reversible statin intolerance

(2011) Charles J. Glueck et al.   CURRENT MEDICAL RESEARCH AND OPINION

Measuring and valuing productivity loss due to poor health: A critical review

(2010) Wei Zhang et al.   SOCIAL SCIENCE & MEDICINE

Cost effectiveness of rosuvastatin in patients at risk of cardiovascular disease based on findings from the JUPITER trial

(2010) Robert L. Ohsfeldt et al.   JOURNAL OF MEDICAL ECONOMICS

Impact of Worksite Wellness Intervention on Cardiac Risk Factors and One-Year Health Care Costs

(2009) Richard V. Milani et al.   AMERICAN JOURNAL OF CARDIOLOGY

Lipid Treatment Assessment Project 2

(2009) David D. Waters et al.   CIRCULATION

Economic Productivity by Age and Sex

(2009) Scott D. Grosse et al.   MEDICAL CARE

Trends in Statin Use and Low-Density Lipoprotein Cholesterol Levels Among US Adults: Impact of the 2001 National Cholesterol Education Program Guidelines

(2008) Devin Mann et al.   ANNALS OF PHARMACOTHERAPY